LTPA2025537I1 - - Google Patents
Info
- Publication number
- LTPA2025537I1 LTPA2025537I1 LTPA2025537C LTPA2025537C LTPA2025537I1 LT PA2025537 I1 LTPA2025537 I1 LT PA2025537I1 LT PA2025537 C LTPA2025537 C LT PA2025537C LT PA2025537 C LTPA2025537 C LT PA2025537C LT PA2025537 I1 LTPA2025537 I1 LT PA2025537I1
- Authority
- LT
- Lithuania
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015082699 | 2015-04-14 | ||
| JP2016041641 | 2016-03-04 | ||
| PCT/JP2016/061859 WO2016167263A1 (ja) | 2015-04-14 | 2016-04-13 | Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LTPA2025537I1 true LTPA2025537I1 (enExample) | 2025-11-10 |
Family
ID=56418770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/JP2016/061859T LT3284480T (lt) | 2015-04-14 | 2016-04-13 | Farmacinė kompozicija, skirta atopinio dermatito profilaktikai ir (arba) gydymui, savo sudėtyje turinti il-31 antagonistą kaip veikliąją medžiagą |
| LTPA2025537C LTPA2025537I1 (enExample) | 2015-04-14 | 2025-10-23 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/JP2016/061859T LT3284480T (lt) | 2015-04-14 | 2016-04-13 | Farmacinė kompozicija, skirta atopinio dermatito profilaktikai ir (arba) gydymui, savo sudėtyje turinti il-31 antagonistą kaip veikliąją medžiagą |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12441804B2 (enExample) |
| EP (1) | EP4650370A2 (enExample) |
| JP (1) | JP5954916B1 (enExample) |
| KR (3) | KR102886159B1 (enExample) |
| CN (1) | CN114848823A (enExample) |
| AU (2) | AU2016248786B2 (enExample) |
| DK (1) | DK3284480T3 (enExample) |
| ES (1) | ES3036076T3 (enExample) |
| FI (2) | FI3284480T3 (enExample) |
| HR (1) | HRP20250972T1 (enExample) |
| HU (1) | HUS2500042I1 (enExample) |
| LT (2) | LT3284480T (enExample) |
| NL (1) | NL301347I2 (enExample) |
| PL (1) | PL3284480T3 (enExample) |
| SI (1) | SI3284480T1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102886159B1 (ko) * | 2015-04-14 | 2025-11-13 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
| KR20250127348A (ko) * | 2018-04-25 | 2025-08-26 | 키닉사 파마슈티컬스, 리미티드 | 항-OSMRß 항체 전달에 의한 피부 질환 또는 장애 치료 |
| MX2022005654A (es) | 2019-11-20 | 2022-06-22 | Chugai Pharmaceutical Co Ltd | Preparacion que contiene anticuerpo. |
| CN115181183B (zh) * | 2022-06-23 | 2023-11-03 | 恺佧生物科技(上海)有限公司 | 一种il-31ra抗体以及其构建方法 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| BR9204244A (pt) | 1992-10-26 | 1994-05-03 | Cofap | Ferro fundido cinzento |
| PL309249A1 (en) | 1992-12-01 | 1995-10-02 | Protein Design Labs | Humanised antibodies against l-selectin |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| FR2729855A1 (fr) | 1995-01-26 | 1996-08-02 | Oreal | Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| JP3946256B2 (ja) | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン５受容体α鎖に対する抗体 |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| CN1241944A (zh) | 1996-12-05 | 2000-01-19 | 乔治敦大学 | 具有抗病毒活性的鼠尾草种类的提取物 |
| JPH11101542A (ja) | 1997-09-29 | 1999-04-13 | Sanyo Electric Co Ltd | 冷蔵庫 |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| JP3979008B2 (ja) | 1998-04-30 | 2007-09-19 | タノックス インコーポレイテッド | Ｇ−ｃｓｆレセプターアゴニスト抗体及びそのスクリーニング方法 |
| FR2780062B1 (fr) | 1998-06-17 | 2000-07-28 | Rhone Poulenc Rorer Sa | Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations |
| CA2330547A1 (en) | 1998-06-24 | 1999-12-29 | Chugai Research Institute For Molecular Medicine, Inc. | Novel hemopoietin receptor proteins |
| DE69934967T2 (de) | 1998-12-08 | 2007-12-06 | Biovation Ltd. | Verfahren zur verminderung der immunogenität von proteinen |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| EP2325316B8 (en) | 1999-06-02 | 2017-04-19 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, NR10 |
| AU7445900A (en) | 1999-09-27 | 2001-04-30 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
| CN1326880A (zh) | 2000-06-06 | 2001-12-19 | 周伟中 | 双层站台火车站 |
| US20030096339A1 (en) | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
| ES2593002T3 (es) | 2000-06-26 | 2016-12-05 | Zymogenetics, Inc. | Receptor ZCYTOR17 de citocina |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| WO2002032925A2 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2002077230A1 (fr) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Variants d'epissage nr10 |
| CN100469793C (zh) | 2001-04-05 | 2009-03-18 | 株式会社免疫生物研究所 | 抗骨桥蛋白抗体及其用途 |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| RU2360923C2 (ru) | 2002-01-18 | 2009-07-10 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| PT1576112E (pt) | 2002-01-18 | 2012-05-25 | Zymogenetics Inc | Multímeros de receptor de citocina zcytor17 |
| ATE431406T1 (de) | 2002-02-25 | 2009-05-15 | Genentech Inc | Neuer typ-1-cytokinrezeptor glm-r |
| RU2320366C2 (ru) | 2002-05-01 | 2008-03-27 | Шеринг Акциенгезельшафт | Новые слитые белки тромбомодулина, обеспечивающие направленный перенос к тканевому фактору, в качестве антикоагулянтов |
| US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
| TW200407335A (en) | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
| KR100499989B1 (ko) | 2002-12-27 | 2005-07-07 | 네오바이오다임 주식회사 | 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법 |
| US20040223970A1 (en) | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
| AU2004229311B2 (en) | 2003-03-04 | 2009-07-09 | Alexion Pharmaceuticals, Inc. | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
| AU2004223836A1 (en) | 2003-03-24 | 2004-10-07 | Zymogenetics, Inc. | Anti-IL-20 antibodies and binding partners and methods of using in inflammation |
| WO2005079566A2 (en) | 2004-02-12 | 2005-09-01 | Lexicon Genetics Incorporated | Gene disruptions, compositions and methods relating thereto |
| KR100624013B1 (ko) | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
| US20060019342A1 (en) | 2004-06-25 | 2006-01-26 | Medimmune, Inc. | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| MX2007007935A (es) | 2004-12-28 | 2007-12-06 | Innate Pharma Sa | Anticuerpos monoclonales contra nkg2a. |
| ES2579758T3 (es) | 2005-01-28 | 2016-08-16 | Zymogenetics, Inc. | Preparaciones homogéneas de IL-31 |
| AU2006214404B2 (en) | 2005-02-14 | 2012-03-08 | Bristol-Myers Squibb Company | Methods of treating skin disorders using an IL-31RA antagonist |
| JP2008530137A (ja) | 2005-02-14 | 2008-08-07 | ザイモジェネティクス，インコーポレイティド | 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| RU2444528C2 (ru) | 2005-05-06 | 2012-03-10 | Займоджинетикс, Инк. | Моноклональные антитела против il-31 и способы применения |
| US7531637B2 (en) | 2005-05-06 | 2009-05-12 | Zymogenetics, Inc. | IL-31 monoclonal antibodies |
| JP2009526756A (ja) | 2006-01-10 | 2009-07-23 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法 |
| AU2007207764B2 (en) | 2006-01-12 | 2012-06-07 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
| RS51723B2 (sr) | 2006-03-23 | 2018-03-30 | Bioarctic Neuroscience Ab | Poboljšana antitela selektivna za protofibrile i njihova primena |
| PT2047863E (pt) | 2006-06-08 | 2013-10-21 | Chugai Pharmaceutical Co Ltd | Prevenção ou tratamento para doença inflamatória |
| WO2007147122A2 (en) | 2006-06-15 | 2007-12-21 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds |
| SI2594586T1 (sl) | 2006-09-01 | 2014-11-28 | Zymogenetics, Inc. | IL-31 monoklonska protitelesa in metode uporabe |
| JP2010512402A (ja) | 2006-12-11 | 2010-04-22 | ワイス エルエルシー | Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法 |
| CN101600456A (zh) | 2006-12-11 | 2009-12-09 | 惠氏公司 | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
| DE602008004296D1 (de) | 2007-02-14 | 2011-02-17 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| SI2426144T1 (sl) | 2007-02-23 | 2019-02-28 | Merck Sharp & Dohme Corp. | Umetno proizvedena anti-IL23P19 antitelesa |
| EP2138576A4 (en) | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
| GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
| WO2009007272A1 (en) | 2007-07-10 | 2009-01-15 | F. Hoffmann-La Roche Ag | Novel formulation |
| AU2008304756B8 (en) | 2007-09-26 | 2015-02-12 | Chugai Seiyaku Kabushiki Kaisha | Anti-IL-6 receptor antibody |
| RU2526512C2 (ru) | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
| CN101874042B9 (zh) * | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| BRPI0821145B8 (pt) | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido |
| WO2009072604A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 抗nr10抗体、およびその利用 |
| WO2009071696A2 (en) | 2007-12-07 | 2009-06-11 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
| KR20160062207A (ko) | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| EP2475376B1 (en) | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| EP2735315B1 (en) | 2011-07-19 | 2019-10-02 | Chugai Seiyaku Kabushiki Kaisha | Stable protein-containing preparation containing argininamide or valinamide |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| ES2981062T3 (es) | 2012-09-07 | 2024-10-07 | Regeneron Pharma | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| EP2970508A4 (en) | 2013-03-15 | 2016-12-14 | Permeon Biologics Inc | GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE |
| US9198898B2 (en) * | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| WO2014208645A1 (ja) * | 2013-06-28 | 2014-12-31 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のｉｌ－３１アンタゴニストによる治療に対する応答を予測する方法 |
| TW202515609A (zh) | 2015-04-14 | 2025-04-16 | 日商中外製藥股份有限公司 | 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物 |
| KR102886159B1 (ko) * | 2015-04-14 | 2025-11-13 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
| GB201703063D0 (en) | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| WO2018156367A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| US10554227B2 (en) * | 2017-03-10 | 2020-02-04 | Western Digital Technologies, Inc. | Decoding optimization for channel mismatch |
| EP3609916A1 (en) | 2017-04-11 | 2020-02-19 | Kiniksa Pharmaceuticals, Ltd. | Stable anti-osmr antibody formulation |
| CN112512480B (zh) | 2018-05-21 | 2024-10-01 | 中外制药株式会社 | 被封入玻璃容器的冷冻干燥制剂 |
| MX2022005654A (es) | 2019-11-20 | 2022-06-22 | Chugai Pharmaceutical Co Ltd | Preparacion que contiene anticuerpo. |
| IL300694A (en) | 2020-09-01 | 2023-04-01 | Chugai Pharmaceutical Co Ltd | A pharmaceutical preparation for the prevention and/or treatment of dialysis pruritus that includes an IL-31 antagonist as an active ingredient |
| JPWO2022113316A1 (enExample) | 2020-11-30 | 2022-06-02 | ||
| CN118613503A (zh) | 2021-12-22 | 2024-09-06 | 中外制药株式会社 | 生物学活性降低的抗体变体 |
-
2016
- 2016-04-13 KR KR1020247006293A patent/KR102886159B1/ko active Active
- 2016-04-13 JP JP2016522817A patent/JP5954916B1/ja active Active
- 2016-04-13 PL PL16780054.9T patent/PL3284480T3/pl unknown
- 2016-04-13 AU AU2016248786A patent/AU2016248786B2/en active Active
- 2016-04-13 DK DK16780054.9T patent/DK3284480T3/da active
- 2016-04-13 SI SI201631915T patent/SI3284480T1/sl unknown
- 2016-04-13 KR KR1020237009639A patent/KR102641898B1/ko active Active
- 2016-04-13 LT LTEPPCT/JP2016/061859T patent/LT3284480T/lt unknown
- 2016-04-13 CN CN202210644000.XA patent/CN114848823A/zh active Pending
- 2016-04-13 HR HRP20250972TT patent/HRP20250972T1/hr unknown
- 2016-04-13 FI FIEP16780054.9T patent/FI3284480T3/fi active
- 2016-04-13 ES ES16780054T patent/ES3036076T3/es active Active
- 2016-04-13 EP EP25186287.6A patent/EP4650370A2/en active Pending
- 2016-04-13 KR KR1020217037698A patent/KR102514173B1/ko active Active
-
2022
- 2022-02-26 AU AU2022201346A patent/AU2022201346B2/en active Active
-
2023
- 2023-08-08 US US18/366,770 patent/US12441804B2/en active Active
-
2025
- 2025-10-22 FI FIC20250033C patent/FIC20250033I1/fi unknown
- 2025-10-23 LT LTPA2025537C patent/LTPA2025537I1/lt unknown
- 2025-10-24 NL NL301347C patent/NL301347I2/nl unknown
- 2025-10-27 HU HUS2500042C patent/HUS2500042I1/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3284480T1 (sl) | 2025-09-30 |
| LT3284480T (lt) | 2025-08-11 |
| AU2016248786A1 (en) | 2017-10-26 |
| EP4650370A2 (en) | 2025-11-19 |
| ES3036076T3 (en) | 2025-09-12 |
| PL3284480T3 (pl) | 2025-11-12 |
| DK3284480T3 (da) | 2025-09-08 |
| KR20210145295A (ko) | 2021-12-01 |
| KR102641898B1 (ko) | 2024-02-27 |
| KR102886159B1 (ko) | 2025-11-13 |
| AU2022201346A1 (en) | 2022-03-24 |
| AU2022201346B2 (en) | 2024-11-21 |
| CN114848823A (zh) | 2022-08-05 |
| KR102514173B1 (ko) | 2023-03-27 |
| AU2016248786B2 (en) | 2022-01-20 |
| HRP20250972T1 (hr) | 2025-10-10 |
| KR20230043246A (ko) | 2023-03-30 |
| JP5954916B1 (ja) | 2016-07-20 |
| KR20240033097A (ko) | 2024-03-12 |
| JPWO2016167263A1 (ja) | 2017-06-01 |
| NL301347I2 (nl) | 2025-11-05 |
| FIC20250033I1 (fi) | 2025-10-22 |
| US20240018249A1 (en) | 2024-01-18 |
| US12441804B2 (en) | 2025-10-14 |
| FI3284480T3 (fi) | 2025-09-11 |
| HUS2500042I1 (hu) | 2025-11-28 |